论文部分内容阅读
目的研究急性白血病患者多药耐药(MDR)表达与治疗效果的关系。方法应用P蛳糖蛋白(p170)单抗对82例急性白血病(AL)患者、12例多发性骨髓瘤(MM)患者、8例非霍奇金淋巴瘤(NHL)Ⅳb期患者进行检测。结果急性白血病、多发骨髓瘤、非霍奇金淋巴瘤Ⅳb患者均有MDR阳性表达,ANLL蛳M5最高(85%),ANLL(46.5%)高于ALL(25%),MM(33.3%),NHL(37.5%)。p170阳性率与AL临床状况密切相关,MDR阳性表达患者对化疗不敏感,完全缓解率低,临床预后差。结论该项检测对指导白血病的治疗、预测化疗效果、判断预后及逆转MDR均有重要意义。
Objective To study the relationship between multidrug resistance (MDR) expression and therapeutic effect in patients with acute leukemia. Methods 82 cases of acute leukemia (AL), 12 cases of multiple myeloma (MM) and 8 cases of non-Hodgkin’s lymphoma (NHL) Ⅳb were detected by P-glycoprotein (p170) monoclonal antibody. Results The positive expression of MDR in acute leukemia, multiple myeloma and non-Hodgkin’s lymphoma Ⅳb was the highest (85%) in ANLL 蛳 M5 and higher (46.5%) in ANLL than in ALL (25%) and MM (33.3%), NHL (37.5%). The positive rate of p170 is closely related to the clinical status of AL. The MDR positive patients are not sensitive to chemotherapy, the complete remission rate is low, and the clinical prognosis is poor. Conclusions This test is of great significance in the treatment of leukemia, predicting the effect of chemotherapy, prognosis and reversing MDR.